Menu
The Hadassah Cancer Research Institute (HCRI) is the translational research institute of Hadassah Medical Organization in Oncology, based in Jerusalem, Israel.
Discoveries made in HCRI labs are driving clinical progress in the quest to diagnose and cure cancer. Among HCRI’s advanced centers of research excellence are: Immuno Oncology, Cancer Epigenetics, early cancer detection, Cell Therapy, Bioinformatics, Precision Radiotherapy and a Biobank.
Our physicians and scientific researchers are developing a multi-disciplined, multi-institution approach to discovering the next-generation treatments to cure cancer. Professor Michal Lotem founded and has led the Hadassah Cancer Research Institute since its inception in 2019.
Our work in this field includes ACT, genetic engineering, and the development of novel ICIs
We focus on cell-free nucleosomes, urine immunograms, and biomarkers for therapeutic decisions
Our efforts in this area involve machine learning for genome analysis and the development of user-friendly electronic health records
This unit is dedicated to early-phase clinical trials
We are invested in identifying predictive bio-markers
Our proactive approach aims to prevent cancer and catch it in its earliest stages
Our Biobank houses a range of biological samples for use in research
A skilled team of physician-scientists highly aware of clinical needs, actively involved in research work.
Academic clinical collaborations with the Hebrew University Faculty of Medicine, benefiting from geographical proximity
Big data silos and Biobank generated in a busy tertiary Oncology Institute, supported by electronic and dynamic documentation interfaces
Strong institutional support of investigator-initiated treatment projects
